ArticleCancer immunology, immunotherapy : CII2009
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
Article in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- β-amino acid substitution in the SIINFEKL antigen alters immunological recognition.Cancer biology & therapy · 2025Article
- Development of Peptide-Based Vaccines for Cancer.Journal of oncology · 2022Review
- Potential association factors for developing effective peptide-based cancer vaccines.Frontiers in immunology · 2022Article
- Targeting Angiogenesis With Peptide Vaccines.Frontiers in immunology · 2019Review
- Mechanisms for enhanced antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein.Oncology letters · 2018Article
- Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma.Oncotarget · 2017Article
- Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice.Journal of translational medicine · 2013Article
- Improving T cell responses to modified peptides in tumor vaccines.Immunologic research · 2013Review
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Review
- Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen.Cancer immunology, immunotherapy : CII · 2009Article
- Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides.The Journal of biological chemistry · 2009Article
- Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity.Molecular immunology · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of tumour antigens recognized by T cells and the features of immune responses directed against them has paved the way to a multitude of clinical studies aimed at boosting anti-tumour T cell immunity as a therapeutic tool for cancer patients. One of the different strategies explored to ameliorate the immunogenicity of tumour antigens in vaccine protocols is represented by the use of optimized peptides or altered peptide ligands, whose amino acid sequence has been modified for improving HLA binding or TCR interaction with respect to native epitopes. However, despite the promising results achieved with preclinical studies, the clinical efficacy of this approach has not yet met the expectations. Although multiple reasons could explain the relative failure of altered peptide ligands as more effective cancer vaccines, the possibility that T cells primed by modified tumour peptides might may be unable to effectively cross-recognize tumour cells has not been sufficiently addressed. Indeed, the introduction of conservative amino acid substitutions may still produce diverse and unpredictable changes in the HLA/peptide interface, with consequent modifications of the TCR repertoire that can interact with the complex. This could lead to the expansion of a broad array of T cells whose TCRs may not necessarily react with equivalent affinity with the original antigenic epitope. Considering the results presently achieved with this vaccine approach, and the emerging availability of alternative strategies for boosting anti-tumour immunity, the use of modified tumour peptides could be reconsidered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.